XPO1-dependent nuclear export as a target for cancer therapy

被引：177

作者：

Azizian, Nancy G. ^{[1
,2
]}

Li, Yulin ^{[1
,2
]}

机构：

[1] Houston Methodist Res Inst, Ctr Immunotherapy Res, 6670 Bertner Ave, Houston, TX 77030 USA

[2] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA

来源：

JOURNAL OF HEMATOLOGY & ONCOLOGY | 2020年 / 13卷 / 01期

关键词：

XPO1; CRM1; Nuclear export; Selective inhibitor of nuclear export (SINE); Selinexor; Cancer; ORDER CHROMOSOME STRUCTURE; PHASE-II TRIAL; LEPTOMYCIN-B; RNA EXPORT; SELECTIVE-INHIBITION; ANTITUMOR EFFICACY; SELINEXOR KPT-330; SOMATIC MUTATIONS; MULTIPLE-MYELOMA; ORAL SELINEXOR;

D O I：

10.1186/s13045-020-00903-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport of hundreds of proteins and multiple RNA species. XPO1 is frequently overexpressed and/or mutated in human cancers and functions as an oncogenic driver. Suppression of XPO1-mediated nuclear export, therefore, presents a unique therapeutic strategy. In this review, we summarize the physiological functions of XPO1 as well as the development of various XPO1 inhibitors and provide an update on the recent clinical trials of the SINE compounds. We also discuss potential future research directions on the molecular function of XPO1 and the clinical application of XPO1 inhibitors.

引用

页数：9

共 106 条

[1] HIGHER-ORDER CHROMOSOME STRUCTURE IS AFFECTED BY COLD-SENSITIVE MUTATIONS IN A SCHIZOSACCHAROMYCES-POMBE GENE CRM1+ WHICH ENCODES A 115-KD PROTEIN PREFERENTIALLY LOCALIZED IN THE NUCLEUS AND AT ITS PERIPHERY [J].

ADACHI, Y ;

YANAGIDA, M .

JOURNAL OF CELL BIOLOGY, 1989, 108 (04) :1195-1207

[2]

Aladhraei Mohammed, 2019, Asian Pac J Cancer Prev, V20, P3747, DOI 10.31557/APJCP.2019.20.12.3747

[3] Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia [J].

Alexander, Thomas B. ;

Lacayo, Norman J. ;

Choi, John K. ;

Ribeiro, Raul C. ;

Pui, Ching-Hon ;

Rubnitz, Jeffrey E. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) :4094-+

[4] AACR Project GENIE: Powering Precision Medicine through an International Consortium [J].

Andre, Fabrice ;

Arnedos, Monica ;

Baras, Alexander S. ;

Baselga, Jose ;

Bedard, Philippe L. ;

Berger, Michael F. ;

Bierkens, Mariska ;

Calvo, Fabien ;

Cerami, Ethan ;

Chakravarty, Debyani ;

Dang, Kristen K. ;

Davidson, Nancy E. ;

Del Vecchio, Fitz Catherine ;

Dogan, Semih ;

DuBois, Raymond N. ;

Ducar, Matthew D. ;

Futreal, P. Andrew ;

Gao Jianjiong ;

Garcia, Francisco ;

Gardos, Stu ;

Gocke, Christopher D. ;

Gross, Benjamin E. ;

Guinney, Justin ;

Heins, Zachary J. ;

Hintzen, Stephanie ;

Horlings, Hugo ;

Hudecek, Jan ;

Hyman, David M. ;

Kamel-Reid, Suzanne ;

Kandoth, Cyriac ;

Kinyua, Walter ;

Kumari, Priti ;

Kundra, Ritika ;

Ladanyi, Marc ;

Lefebvre, Celine ;

LeNoue-Newton, Michele L. ;

Lepisto, Eva M. ;

Levy, Mia A. ;

Lindeman, Neal, I ;

Lindsay, James ;

Liu, David ;

Lu Zhibin ;

MacConaill, Laura E. ;

Ian, Maurer ;

Maxwell, David S. ;

Meijer, Gerrit A. ;

Meric-Bernstam, Funda ;

Micheel, Christine M. ;

Miller, Clinton ;

Mills, Gordon .

CANCER DISCOVERY, 2017, 7 (08) :818-831

[5] Crm1 is a mitotic effector of Ran-GTP in somatic cells [J].

Arnaoutov, A ;

Azuma, Y ;

Ribbeck, K ;

Joseph, J ;

Boyarchuk, Y ;

Karpova, T ;

McNally, J ;

Dasso, M .

NATURE CELL BIOLOGY, 2005, 7 (06) :626-U27

[6] Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma [J].

Azmi, Asfar S. ;

Khan, Husain Yar ;

Muqbil, Irfana ;

Aboukameel, Amro ;

Neggers, Jasper E. ;

Daelemans, Dirk ;

Mahipal, Amit ;

Dyson, Gregory ;

Kamgar, Mandana ;

Al-Hallak, Mohammad Najeeb ;

Tesfaye, Anteneh ;

Kim, Steve ;

Shidham, Vinod ;

Mohammad, Ramzi M. ;

Philip, Philip A. .

CLINICAL CANCER RESEARCH, 2020, 26 (06) :1338-1348

[7] Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration [J].

Azmi, Asfar S. ;

Li, Yiwei ;

Muqbil, Irfana ;

Aboukameel, Amro ;

Senapedis, William ;

Baloglu, Erkan ;

Landesman, Yosef ;

Shacham, Sharon ;

Kauffman, Michael G. ;

Philip, Philip A. ;

Mohammad, Ramzi M. .

ONCOTARGET, 2017, 8 (47) :82144-82155

[8] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma [J].

Bahlis, Nizar J. ;

Sutherland, Heather ;

White, Darrell ;

Sebag, Michael ;

Lentzsch, Suzanne ;

Kotb, Rami ;

Venner, Christopher P. ;

Gasparetto, Cristina ;

Del Col, Aldo ;

Neri, Paola ;

Reece, Donna ;

Kauffman, Michael ;

Shacham, Sharon ;

Unger, T. J. ;

Jeha, Jacqueline ;

Saint-Martin, Jean-Richard ;

Shah, Jatin ;

Chen, Christine .

BLOOD, 2018, 132 (24) :2546-2554

[9] The strategy for coupling the RanGTP gradient to nuclear protein export [J].

Becskei, A ;

Mattaj, LW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1717-1722

[10] Comprehensive Identification of Somatic Mutations in Chronic Lymphocytic Leukemia [J].

Bergsagel, P. Leif ;

Kuehl, W. Michael .

CANCER CELL, 2011, 20 (01) :5-7

← 1 2 3 4 5 6 7 8 9 10 →